Skip to main content

Advertisement

SpringerLink
Log in

The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

There has been concerning about women receiving depot medroxyprogesterone acetate (DMPA) contraception because of the prolonged hypoestrogenemic state regarding the potential negative effects on bone health. This study showed that DMPA exposure is associated with increased fracture risk and that fracture risk increases with longer DMPA exposure.

Introduction

DMPA has been associated with impaired bone mineral acquisition during adolescence and accelerated bone loss in later life. We performed this large population-based study to assess the association between use of DMPA or combined oral contraceptives and the incident risk of fracture.

Methods

We identified 4189 women between 20 and 44 years of age with a first-time fracture diagnosis, matched them with 4189 random controls using the Disease Analyzer database and investigated the relation with DMPA exposure.

Results

Overall, 11 % of the fracture cases and 7.7 % of the controls had DMPA use recorded. The adjusted OR for developing a fracture in patients with current use of DMPA compared to non-users was 0.97 (95 % CI 0.51–1.86), 2.41 (95 % CI 1.42–4.08), and 1.46 (95 % CI 0.96–2.23) for 1–2, 3–9, and ≥10 prescriptions, respectively. The adjusted OR for developing a fracture in patients with past use of DMPA compared to non-users was 0.96 (95 % CI 0.73–1.26), 1.14 (95 % CI 0.86–1.51), and 1.55 (95 % CI 1.07–2.27) for 1–2, 3–9, and ≥10 prescriptions, respectively. The highest fracture risk was identified in young patients less than 30 years with longer DMPA exposure (≥10 prescriptions; OR 3.04, 95 % CI 1.36–6.81), as well as in patients in the late reproductive years with past use of DMPA (OR 1.72, 95 % CI 1.13–2.63).

Conclusions

Our results indicate that DMPA exposure is associated with increased fracture risk and may have negative effects on bone metabolism, resulting in impaired bone mineral acquisition during adolescence and accelerated bone loss in adult life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kyvernitakis I, Hadji P (2015) Bone health in adolescent gynecology. Gynakologe (48):299–305.

  2. Miller KK, Klibanski A (1999) Clinical review 106: amenorrheic bone loss. J Clin Endocrinol Metab 84(6):1775–1783.

    CAS  PubMed  Google Scholar 

  3. Kaunitz AM, Rosenfield A (1993) Injectable contraception with depot medroxyprogesterone acetate. Current status. Drugs 45(6):857–865.

    Article  CAS  PubMed  Google Scholar 

  4. Cromer BA, Berg-Kelly KS, Van Groningen JP, Seimer BS, Ruusuvaara L (1998) Depot medroxyprogesterone acetate (Depo-Provera) and levonorgestrel (Norplant) use in adolescents among clinicians in northern Europe and the United States. The Journal of adolescent health : official publication of the Society for Adolescent Medicine 23(2):74–80.

    Article  CAS  Google Scholar 

  5. Michaelsson K, Baron JA, Farahmand BY, Persson I, Ljunghall S (1999) Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet 353(9163):1481–1484.

    Article  CAS  PubMed  Google Scholar 

  6. Hillard TC, Stevenson JC (1991) Role of oestrogen in the development of osteoporosis. Calcif Tissue Int 49 Suppl:S55–S59.

    Article  CAS  PubMed  Google Scholar 

  7. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR (2006) Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 74(2):90–99.

    Article  CAS  PubMed  Google Scholar 

  8. Herrmann M, Seibel MJ (2010) The effects of hormonal contraceptives on bone turnover markers and bone health. Clin Endocrinol 72(5):571–583.

    Article  CAS  Google Scholar 

  9. Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR (2010) Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab 95(11):4909–4916.

    Article  CAS  PubMed  Google Scholar 

  10. Watson KC, Lentz MJ, Cain KC (2006) Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities. Womens Health Issues 16(6):346–352.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lappe JM, Stegman MR, Recker RR (2001) The impact of lifestyle factors on stress fractures in female army recruits. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 12(1):35–42.

    Article  CAS  Google Scholar 

  12. Vestergaard P, Rejnmark L, Mosekilde L (2008) The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception 78(6):459–464.

    Article  CAS  PubMed  Google Scholar 

  13. Becher H, Kostev K, Schroder-Bernhardi D (2009) Validity and representativeness of the “disease analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47(10):617–626.

    Article  CAS  PubMed  Google Scholar 

  14. Kostev K, Haas G (eds) (2011) Medical Care in Germany. Optimus, Göttingen.

    Google Scholar 

  15. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 23(1):223–231.

    Article  CAS  Google Scholar 

  16. Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P (2012) Persistence and compliance of medications used in the treatment of osteoporosis—analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 50(5):315–322.

    Article  CAS  PubMed  Google Scholar 

  17. Kyvernitakis I, Kostev K, Kurth A, Albert US, Hadji P (2014) Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 25(12):2721–2728.

    Article  CAS  Google Scholar 

  18. Kyvernitakis I, Kostev K, Hars O, Albert US, Hadji P (2015) Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study ERA. Climacteric : the journal of the International Menopause Society:1–22.

  19. Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H, et al. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int. 2016.

  20. Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D, et al. (2003) A checklist for retrospective database studies—report of the ISPOR task force on retrospective databases. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 6(2):90–97.

    Article  Google Scholar 

  21. Nappi C, Bifulco G, Tommaselli GA, Gargano V, Di Carlo C (2012) Hormonal contraception and bone metabolism: a systematic review. Contraception 86(6):606–621.

    Article  CAS  PubMed  Google Scholar 

  22. De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, et al. (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 16(11):1330–1338.

    Article  CAS  Google Scholar 

  23. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z (1996) A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 129(5):671–676.

    Article  CAS  PubMed  Google Scholar 

  24. Walsh JS, Henry YM, Fatayerji D, Eastell R (2009) Lumbar spine peak bone mass and bone turnover in men and women: a longitudinal study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20(3):355–362.

    Article  CAS  Google Scholar 

  25. Walsh JS, Eastell R, Peel NF (2008) Effects of depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab 93(4):1317–1323.

    Article  CAS  PubMed  Google Scholar 

  26. Lopez LM, Chen M, Mullins Long S, Curtis KM, Helmerhorst FM (2015) Steroidal contraceptives and bone fractures in women: evidence from observational studies. The Cochrane Database of Systematic Reviews 7:CD009849.

    Google Scholar 

  27. Lopez LM, Grimes DA, Schulz KF, Curtis KM, Chen M (2014) Steroidal contraceptives: effect on bone fractures in women. The Cochrane Database of Systematic Reviews 6:CD006033.

    Google Scholar 

  28. Huang SY, Grimsrud CD, Provus J, Hararah M, Chandra M, Ettinger B, et al. (2012) The impact of subtrochanteric fracture criteria on hip fracture classification. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 23(2):743–750.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Bürgerhospital Frankfurt, Goethe-University of Frankfurt, Nibelungenallee 37-41, 60318, Frankfurt am Main, Germany

    I. Kyvernitakis

  2. Faculty of Medicine, Philipps-University of Marburg, Marburg, Germany

    I. Kyvernitakis & T. Nassour

  3. IMS HEALTH GmbH & Co. OHG, Epidemiology, Real World Evidence Solutions, Darmstädter Landstraße 108, 60598, Frankfurt, Germany

    K. Kostev

  4. Department of Bone Oncology, Gyn. Endocrinology and Reproductive Medicine, Nordwest Hospital, Goethe-University of Frankfurt, Frankfurt a.M., Germany

    F. Thomasius & P. Hadji

Authors
  1. I. Kyvernitakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Kostev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Nassour
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Thomasius
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Hadji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Kyvernitakis.

Ethics declarations

The study was conducted according to the German law and the declaration of Helsinki.

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kyvernitakis, I., Kostev, K., Nassour, T. et al. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int 28, 291–297 (2017). https://doi.org/10.1007/s00198-016-3714-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-016-3714-4

Keywords

Search

Navigation